xylometazoline

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	0.917		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	4.571		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	6.637	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	5.495	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	21.710	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	33.540	%	High	1
herg	hERG pIC50	5.053	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	3.811	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	15.996	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	28.760	%	High	1
kinase-safety-class	ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,TEK,TTK	44
kinase-selectivity-class	BRAF,GRK2,PDK4	3
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	3.724		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	45.709		High	1
mppb	Mouse plasma protein binding (% unbound)	17.780		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	11.885		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	30.580	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	65.615	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	48.040	%	High	1
rppb	Rat plasma protein binding (% unbound)	33.230	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	870.964	uM	High	1

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Reversible cerebral vasoconstriction syndrome	143.47	26.60	30	2020	4100	90622297
Rebound nasal congestion	109.12	26.60	13	2037	35	90626362
Thunderclap headache	105.05	26.60	16	2034	352	90626045
Analgesic therapy	81.62	26.60	14	2036	658	90625739
Antacid therapy	80.01	26.60	14	2036	740	90625657
Appendicolith	79.88	26.60	14	2036	747	90625650
Drug therapy	79.03	26.60	14	2036	795	90625602
Anticoagulant therapy	78.89	26.60	14	2036	803	90625594
Atrial septal defect	73.81	26.60	20	2030	8214	90618183
Foetal exposure during pregnancy	67.25	26.60	28	2022	42947	90583450
Subarachnoid haemorrhage	58.49	26.60	20	2030	17884	90608513
Hyperphosphataemia	57.77	26.60	14	2036	3697	90622700
Blood phosphorus increased	55.66	26.60	14	2036	4304	90622093
Aortic stenosis	50.34	26.60	14	2036	6322	90620075
Blood uric acid increased	47.63	26.60	14	2036	7690	90618707
Activated partial thromboplastin time prolonged	47.41	26.60	14	2036	7811	90618586
End stage renal disease	46.16	26.60	14	2036	8557	90617840
Appendicitis	43.71	26.60	14	2036	10217	90616180
Haemangioma congenital	43.67	26.60	8	2042	548	90625849
Cerebral artery stenosis	43.18	26.60	8	2042	583	90625814
Blood calcium increased	41.45	26.60	14	2036	12044	90614353
Nasal turbinate hypertrophy	39.64	26.60	8	2042	913	90625484
Gout	36.87	26.60	14	2036	16845	90609552
Anticholinergic syndrome	35.88	26.60	9	2041	2734	90623663
Nasal mucosal disorder	34.05	26.60	8	2042	1849	90624548
Blood test abnormal	33.92	26.60	14	2036	20938	90605459
Nasal septum deviation	33.69	26.60	8	2042	1935	90624462
Hyperlipidaemia	32.71	26.60	14	2036	22902	90603495
Bacterial infection	32.40	26.60	14	2036	23430	90602967
Cardiogenic shock	31.83	26.60	14	2036	24454	90601943
Allergy to animal	29.67	26.60	7	2043	1647	90624750
Mastocytosis	27.78	26.60	6	2044	950	90625447

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	376.82	92.80	125	7216	13331	42600663
Appendicitis	331.89	92.80	127	7214	20486	42593508
Blood phosphorus increased	313.64	92.80	107	7234	12418	42601576
Myasthenia gravis	309.29	92.80	113	7228	16024	42597970
Stress	273.51	92.80	139	7202	44073	42569921
Ventricular fibrillation	266.18	92.80	121	7220	30002	42583992
Hyperphosphataemia	260.09	92.80	94	7247	12910	42601084
Analgesic therapy	258.51	92.80	79	7262	6445	42607549
Cardiogenic shock	249.77	92.80	122	7219	35518	42578476
Blood uric acid increased	240.16	92.80	93	7248	15454	42598540
Neuralgia	235.98	92.80	106	7235	25541	42588453
Hypophosphataemia	233.13	92.80	99	7242	20846	42593148
Drug therapy	226.39	92.80	71	7270	6309	42607685
Ascites	222.55	92.80	132	7209	56546	42557448
Sleep disorder therapy	220.98	92.80	71	7270	6823	42607171
Bacterial infection	218.23	92.80	103	7238	27776	42586218
Incorrect route of product administration	212.64	92.80	97	7244	24208	42589786
Dry mouth	205.48	92.80	111	7230	39768	42574226
Abdominal distension	198.79	92.80	134	7207	71601	42542393
Blood cholesterol increased	197.69	92.80	95	7246	26646	42587348
Iron deficiency	184.50	92.80	70	7271	10991	42603003
Multiple organ dysfunction syndrome	181.78	92.80	143	7198	96892	42517102
Hyponatraemia	174.03	92.80	142	7199	101320	42512674
Diabetes mellitus	161.02	92.80	110	7231	59977	42554017
Intentional product misuse	158.06	92.80	110	7231	61790	42552204
Swelling	148.27	92.80	101	7240	54784	42559210
Antacid therapy	144.68	92.80	47	7294	4670	42609324
Anticoagulant therapy	142.40	92.80	46	7295	4489	42609505
Thrombosis	141.33	92.80	107	7234	68404	42545590
Chronic obstructive pulmonary disease	140.07	92.80	103	7238	63011	42550983
General physical health deterioration	137.93	92.80	149	7192	151097	42462897
Sleep disorder	128.67	92.80	88	7253	48007	42565987
Activated partial thromboplastin time prolonged	128.17	92.80	60	7281	15843	42598151
Somnolence	121.62	92.80	135	7206	140970	42473024
Ulcer	120.17	92.80	58	7283	16383	42597611
Drug intolerance	120.07	92.80	104	7237	80320	42533674
End stage renal disease	110.80	92.80	55	7286	16503	42597491
Troponin increased	103.48	92.80	55	7286	19007	42594987
Drug hypersensitivity	103.10	92.80	105	7236	99284	42514710
Blood calcium increased	100.77	92.80	42	7299	8412	42605582
Hyperlipidaemia	94.55	92.80	54	7287	21462	42592532
Gout	93.67	92.80	59	7282	27996	42585998

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	526.74	45.70	139	8974	14116	110566070
Appendicitis	439.98	45.70	141	8972	28323	110551863
Blood phosphorus increased	425.43	45.70	121	8992	16219	110563967
Analgesic therapy	377.07	45.70	93	9020	7191	110572995
Myasthenia gravis	375.70	45.70	117	8996	21394	110558792
Hyperphosphataemia	367.25	45.70	108	9005	16273	110563913
Drug therapy	336.92	45.70	85	9028	7206	110572980
Blood uric acid increased	334.04	45.70	107	9006	21422	110558764
Ventricular fibrillation	333.25	45.70	126	8987	41187	110538999
Cardiogenic shock	326.61	45.70	136	8977	57202	110522984
Sleep disorder therapy	290.93	45.70	76	9037	7395	110572791
Ascites	290.33	45.70	145	8968	92663	110487523
Bacterial infection	288.68	45.70	117	8996	45919	110534267
Hypophosphataemia	277.70	45.70	104	9009	33078	110547108
Neuralgia	269.34	45.70	113	9000	48365	110531821
Stress	267.32	45.70	143	8970	105205	110474981
Antacid therapy	238.87	45.70	61	9052	5423	110574763
Anticoagulant therapy	235.32	45.70	60	9053	5301	110574885
Multiple organ dysfunction syndrome	228.79	45.70	147	8966	151563	110428623
Diabetes mellitus	219.17	45.70	123	8990	99258	110480928
Iron deficiency	219.11	45.70	75	9038	18401	110561785
Abdominal distension	214.30	45.70	149	8964	174954	110405232
Incorrect route of product administration	205.84	45.70	102	9011	63959	110516227
Activated partial thromboplastin time prolonged	201.38	45.70	74	9039	22294	110557892
Chronic obstructive pulmonary disease	195.38	45.70	118	8995	109040	110471146
Hyponatraemia	187.48	45.70	150	8963	217503	110362683
End stage renal disease	185.80	45.70	69	9044	21404	110558782
Thrombosis	180.49	45.70	112	9001	108550	110471636
Intentional product misuse	171.71	45.70	117	8996	132787	110447399
Gout	159.78	45.70	72	9041	36494	110543692
Sepsis	151.01	45.70	159	8954	327187	110252999
Dry mouth	149.52	45.70	127	8986	199821	110380365
Blood calcium increased	148.87	45.70	56	9057	17984	110562202
Hyperlipidaemia	148.46	45.70	68	9045	35780	110544406
Aortic stenosis	139.31	45.70	49	9064	13010	110567176
Troponin increased	137.67	45.70	61	9052	29705	110550481
Somnolence	130.96	45.70	141	8972	297308	110282878
Blood test abnormal	127.20	45.70	57	9056	28497	110551689
Reversible cerebral vasoconstriction syndrome	122.64	45.70	35	9078	4726	110575460
Ulcer	121.90	45.70	63	9050	43053	110537133
Constipation	121.04	45.70	148	8965	357638	110222548
Blood cholesterol increased	119.28	45.70	108	9005	184677	110395509
General physical health deterioration	117.34	45.70	159	8954	425136	110155050
Congenital hiatus hernia	108.99	45.70	34	9079	6225	110573961
Pulmonary embolism	107.44	45.70	109	9004	214365	110365821
Bronchopulmonary aspergillosis allergic	99.06	45.70	34	9079	8392	110571794
Rebound nasal congestion	96.84	45.70	14	9099	48	110580138
Bacteroides infection	91.37	45.70	25	9088	2894	110577292
Sleep disorder	88.77	45.70	95	9018	198549	110381637
Abdominal pain	80.35	45.70	148	8965	512841	110067345
Thunderclap headache	77.13	45.70	16	9097	562	110579624
Total lung capacity decreased	77.03	45.70	27	9086	7087	110573099
Drug intolerance	68.32	45.70	121	8992	406391	110173795
Benign prostatic hyperplasia	67.43	45.70	32	9081	18202	110561984
Pleuritic pain	64.86	45.70	30	9083	16110	110564076
Drug hypersensitivity	63.61	45.70	125	8988	453965	110126221
Micturition urgency	62.68	45.70	31	9082	19289	110560897
Swelling	60.91	45.70	106	9007	350935	110229251
Respiratory symptom	57.63	45.70	27	9086	14918	110565268
Aspiration	57.10	45.70	34	9079	30499	110549687
Anaemia	55.31	45.70	132	8981	546954	110033232
Condition aggravated	51.73	45.70	155	8958	734681	109845505
Lung opacity	51.04	45.70	23	9090	11629	110568557
Breath sounds abnormal	49.36	45.70	29	9084	25375	110554811
Cardiovascular disorder	46.92	45.70	27	9086	22733	110557453

Source	Code	Description
ATC	R01AA07	RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Sympathomimetics, plain
ATC	R01AB06	RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Sympathomimetics, combinations excl. corticosteroids
ATC	S01GA03	SENSORY ORGANS OPHTHALMOLOGICALS DECONGESTANTS AND ANTIALLERGICS Sympathomimetics used as decongestants
ATC	S01GA53	SENSORY ORGANS OPHTHALMOLOGICALS DECONGESTANTS AND ANTIALLERGICS Sympathomimetics used as decongestants
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D014662	Vasoconstrictor Agents
MeSH PA	D014663	Nasal Decongestants
MeSH PA	D019141	Respiratory System Agents
CHEBI has role	CHEBI:77715	nasal decongestant

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

xylometazoline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Disease	Relation	SNOMED_ID	DOID
Nasal discharge	indication	64531003
Nasal congestion	indication	68235000
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Heart disease	contraindication	56265001	DOID:114
Diabetes mellitus	contraindication	73211009	DOID:9351
Transsphenoidal hypophysectomy	contraindication	171948002

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN	AGONIST	Ki	5.98	PDSP	SCIENTIFIC LITERATURE
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	7.04	CHEMBL
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN		Ki	7.89	CHEMBL
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	9.15	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	7.82	PDSP
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	6.89	PDSP
Adrenergic receptor alpha-2	GPCR		ADA2B_RAT ADA2C_RAT ADA2A_RAT		IC50	7.64	CHEMBL
Adrenergic receptor alpha-1	GPCR		ADA1B_RAT ADA1D_RAT ADA1A_RAT		IC50	6.24	CHEMBL
Adrenergic receptor alpha	GPCR		ADA1B_RAT ADA2B_RAT ADA2C_RAT ADA2A_RAT ADA1D_RAT ADA1A_RAT		Ki	8.32	CHEMBL

ID	Source
4020518	VUID
N0000148237	NUI
D00757	KEGG_DRUG
1218-35-5	SECONDARY_CAS_RN
4020500	VANDF
4020518	VANDF
C0078643	UMLSCUI
CHEBI:10082	CHEBI
CHEMBL312448	ChEMBL_ID
DB06694	DRUGBANK_ID
CHEMBL1256400	ChEMBL_ID
C009695	MESH_SUPPLEMENTAL_RECORD_UI
5709	PUBCHEM_CID
517	IUPHAR_LIGAND_ID
809	INN_ID
WPY40FTH8K	UNII
226046	RXNORM
12647	MMSL
5697	MMSL
001804	NDDF
004727	NDDF
372841007	SNOMEDCT_US
75327003	SNOMEDCT_US
76289007	SNOMEDCT_US
WPY40FTH8K	INXIGHT DRUGS

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
SinosilNasal Decongestant	HUMAN OTC DRUG LABEL	1	44237-007	SPRAY	0.02 mL	NASAL	OTC monograph final	14 sections
Metarivin Soln. 0.1%	HUMAN OTC DRUG LABEL	1	72988-0030	LIQUID	1 mg	NASAL	unapproved drug other	7 sections